source Post navigation Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025 – News-Medical Australian MPS learn more about low carb diet on visit to UK – diabetes.co.uk